Eric C Holland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4211685/publications.pdf

Version: 2024-02-01

109 papers	15,893 citations	53794 45 h-index	38395 95 g-index
113 all docs	113 docs citations	113 times ranked	21064 citing authors

#	Article	IF	Citations
1	A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery, 2001, 95, 190-198.	1.6	2,484
2	CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine, 2013, 19, 1264-1272.	30.7	1,812
3	Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature Genetics, 2000, 25, 55-57.	21.4	827
4	PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells. Cell Stem Cell, 2009, 4, 226-235.	11.1	740
5	Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Reviews Cancer, 2010, 10, 319-331.	28.4	660
6	PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes and Development, 2001, 15, 1913-1925.	5.9	611
7	Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520.	27.6	540
8	Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells. Cell Stem Cell, 2010, 6, 141-152.	11.1	493
9	The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science, 2016, 352, aad3018.	12.6	477
10	PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes and Development, 2008, 22, 436-448.	5.9	413
11	Osteopontin-CD44 Signaling in the Glioma Perivascular Niche Enhances Cancer Stem Cell Phenotypes and Promotes Aggressive Tumor Growth. Cell Stem Cell, 2014, 14, 357-369.	11.1	411
12	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
13	Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma. Cancer Cell, 2014, 26, 288-300.	16.8	322
14	Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes and Development, 2017, 31, 774-786.	5.9	313
15	Corticosteroids compromise survival in glioblastoma. Brain, 2016, 139, 1458-1471.	7.6	271
16	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	7.7	271
17	Tissue mechanics promote IDH1-dependent HIF1Î±â€“tenascin C feedback to regulate glioblastomaÂaggression. Nature Cell Biology, 2016, 18, 1336-1345.	10.3	259
18	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Translational Medicine, 2015, 7, 274ra17.	12.4	257

#	Article	IF	Citations
19	Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules. Cell, 2014, 156, 603-616.	28.9	241
20	Modeling Adult Gliomas Using RCAS/t-va Technology. Translational Oncology, 2009, 2, 89-IN6.	3.7	238
21	Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. Science Translational Medicine, 2015, 7, 271ra7.	12.4	236
22	Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies. Cancer Research, 2006, 66, 3355-3359.	0.9	205
23	Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis. Cancer Research, 2004, 64, 4783-4789.	0.9	201
24	Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Letters, 2006, 232, 139-147.	7.2	189
25	mTOR Promotes Survival and Astrocytic Characteristics Induced by Pten/Akt Signaling in Glioblastoma. Neoplasia, 2005, 7, 356-368.	5.3	165
26	In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5248-5253.	7.1	152
27	The perivascular niche microenvironment in brain tumor progression. Cell Cycle, 2010, 9, 3084-3093.	2.6	147
28	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathologica Communications, 2017, 5, 39.	5.2	110
29	Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nature Communications, 2020, 11, 4997.	12.8	109
30	IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nature Cell Biology, 2019, 21, 1003-1014.	10.3	107
31	miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes Tumorigenesis. PLoS ONE, 2012, 7, e33844.	2.5	106
32	Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma. Cancer Cell, 2016, 29, 669-683.	16.8	98
33	High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe. Theranostics, 2016, 6, 1075-1084.	10.0	96
34	Human glioblastomaâ€associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples. Glia, 2016, 64, 1416-1436.	4.9	90
35	Suppression of autophagy impedes glioblastoma development and induces senescence. Autophagy, 2016, 12, 1431-1439.	9.1	89
36	Wnt-mediated endothelial transformation into mesenchymal stem cellâ€“like cells induces chemoresistance in glioblastoma. Science Translational Medicine, 2020, 12, .	12.4	86

#	Article	IF	Citations
37	Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. Cancer Research, 2018, 78, 3718-3730.	0.9	83
38	Glioblastoma: Molecular Analysis and Clinical Implications. Annual Review of Medicine, 2013, 64, 59-70.	12.2	81
39	Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8149-8154.	7.1	80
40	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. OncoImmunology, 2019, 8, e1655360.	4.6	76
41	Recruited Cells Can Become Transformed and Overtake PDGF-Induced Murine Gliomas In Vivo during Tumor Progression. PLoS ONE, 2011, 6, e20605.	2.5	72
42	Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Science Advances, 2020, 6, eaaz3221.	10.3	67
43	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. Nature Communications, 2019, 10, 3914.	12.8	65
44	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. Developmental Biology, 2021, 475, 205-221.	2.0	62
45	A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-ÎºB. Cell Reports, 2018, 23, 3787-3797.	6.4	53
46	Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain. Nature Cancer, 2022, 3, 25-42.	13.2	52
47	Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1. EMBO Journal, 2007, 26, 4683-4693.	7.8	50
48	Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. Genes and Development, 2020, 34, 1051-1064.	5.9	48
49	Big data visualization identifies the multidimensional molecular landscape of human gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5394-5399.	7.1	45
50	ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Scientific Reports, 2016, 6, 25956.	3.3	45
51	Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. , 2020, 8, e001356.		44
52	Variability in estimated gene expression among commonly used RNA-seq pipelines. Scientific Reports, 2020, 10, 2734.	3.3	43
53	Oncogenic Signaling Is Dominant to Cell of Origin and Dictates Astrocytic or Oligodendroglial Tumor Development from Oligodendrocyte Precursor Cells. Journal of Neuroscience, 2014, 34, 14644-14651.	3.6	42
54	Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes and Development, 2018, 32, 512-523.	5.9	40

#	Article	IF	Citations
55	Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. IScience, 2018, 9, 71-83.	4.1	38
56	Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2131-2139.	3.3	37
57	Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma. Cancer Research, 2011, 71, 6174-6183.	0.9	35
58	Antiâ€“PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro-Oncology, 2020, 22, 639-651.	1.2	34
59	Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment. Neuro-Oncology, 2018, 20, 355-366.	1.2	32
60	Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. Journal of Neuropathology and Experimental Neurology, 2019, 78, 1002-1010.	1.7	32
61	Personalized Medicine for Gliomas. , 2015, 6, 89.		31
62	Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. Neuro-Oncology, 2019, 21, 819-821.	1.2	31
63	Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro-Oncology, 2018, 20, 1368-1373.	1.2	28
64	A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways. Nature Communications, 2020, 11, 2977.	12.8	26
65	Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight, 2019, 4, .	5.0	24
66	Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. OncoImmunology, 2020, 9, 1730538.	4.6	23
67	Regularized quantile regression under heterogeneous sparsity with application to quantitative genetic traits. Computational Statistics and Data Analysis, 2016, 95, 222-239.	1.2	22
68	Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Neoplasia, 2016, 18, 82-89.	5.3	21
69	Identification of Global Alteration of Translational Regulation in Glioma In Vivo. PLoS ONE, 2012, 7, e46965.	2.5	21
70	Metabolic Profiling of Dividing Cells in Live Rodent Brain by Proton Magnetic Resonance Spectroscopy (1HMRS) and LCModel Analysis. PLoS ONE, 2014, 9, e94755.	2.5	18
71	Machine learning identifies molecular regulators and therapeutics for targeting SARSâ€CoV2â€induced cytokine release. Molecular Systems Biology, 2021, 17, e10426.	7.2	18
72	TRRAP and the Maintenance of Stemness in Gliomas. Cell Stem Cell, 2010, 6, 6-7.	11.1	16

#	Article	IF	Citations
73	C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Acta Neuropathologica Communications, 2021, 9, 36.	5.2	14
74	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Scientific Reports, 2021, 11, 9362.	3.3	14
75	Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. Nature Biomedical Engineering, 2021, 5, 346-359.	22.5	13
76	The Essentials of Multiomics. Oncologist, 2022, 27, 272-284.	3.7	11
77	Sox2, a marker for stemâ€like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. EMBO Journal, 2014, 33, 1984-1986.	7.8	10
78	Analysis and visualization of linked molecular and clinical cancer data by using Oncoscape. Nature Genetics, 2018, 50, 1203-1204.	21.4	10
79	A brain-penetrant microtubule-targeting agent that disrupts hallmarks of glioma tumorigenesis. Neuro-Oncology Advances, 2021, 3, vdaa165.	0.7	10
80	Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9. Neuro-Oncology, 2019, 21, 1607-1609.	1.2	9
81	Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years. Neurosurgery, 2019, 85, E322-E331.	1.1	9
82	Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival. British Journal of Cancer, 2022, 127, 422-435.	6.4	9
83	Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes. Acta Neuropathologica Communications, 2020, 8, 203.	5.2	8
84	Mathematical modeling of PDGF-driven glioma reveals the dynamics of immune cells infiltrating into tumors. Neoplasia, 2020, 22, 323-332.	5.3	8
85	Multimodal singleâ€cell analysis reveals distinct radioresistant stemâ€like and progenitor cell populations in murine glioma. Glia, 2020, 68, 2486-2502.	4.9	8
86	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. Clinical Cancer Research, 2020, 26, 2457-2460.	7.0	8
87	Leveraging the replicationâ€competent avianâ€like sarcoma virus/tumor virus receptorâ€A system for modeling human gliomas. Glia, 2021, 69, 2059-2076.	4.9	7
88	Rethinking glioma treatment strategy. Oncotarget, 2014, 5, 9532-9533.	1.8	7
89	Olverembatinib inhibits SARSâ€CoVâ€2â€Omicron variantâ€mediated cytokine release in human peripheral blood mononuclear cells. EMBO Molecular Medicine, 2022, 14, e15919.	6.9	7
90	Stochastic growth pattern of untreated human glioblastomas predicts the survival time for patients. Scientific Reports, 2020, 10, 6642.	3.3	5

#	Article	IF	Citations
91	Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. Neurosurgical Focus, 2020, 49, E11.	2.3	4
92	Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma. Acta Neuropathologica Communications, 2021, 9, 191.	5.2	4
93	Radiogenomic modeling predicts survival-associated prognostic groups in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab004.	0.7	3
94	OUP accepted manuscript. Neuro-Oncology, 2021, 23, S4-S15.	1.2	3
95	Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion. Trends in Molecular Medicine, 2017, 23, 773-776.	6.7	2
96	The molecular landscape of adult diffuse gliomas and relevance to clinical trials. Oncotarget, 2019, 10, 1758-1759.	1.8	2
97	GENE-04. THE ONCOGENIC FUNCTIONS OF YAP1-GENE FUSIONS CAN BE INHIBITED BY DISRUPTION OF YAP1-TEAD INTERACTION. Neuro-Oncology, 2019, 21, vi98-vi98.	1.2	1
98	Glioma Stem-like Cells Keep Their H3.3 Variant Levels at Bay. Cancer Cell, 2015, 28, 679-680.	16.8	0
99	PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN. Neuro-Oncology, 2018, 20, vi169-vi170.	1.2	0
100	TMIC-05. ABSCOPAL IMMUNE RESPONSE IN GLIOBLASTOMA ELICITED BY MIR124-ATTENUATED ONCOLYTIC HERPES SIMPLEX VIRUS 1 ARMED WITH UL16 BINDING PROTEIN 3. Neuro-Oncology, 2018, 20, vi256-vi257.	1.2	0
101	TMIC-53. IDENTIFICATION OF MYELOID CELL-DERIVED TRANSCRIPTS IN GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi268-vi268.	1.2	0
102	TMOD-30. ANTI-PD-L1 ANTIBODY ENHANCES RADIATION INDUCED ABSCOPAL RESPONSE IN MURINE BRAIN TUMORS. Neuro-Oncology, 2018, 20, vi275-vi275.	1.2	0
103	RTHP-27. PATTERNS OF FAILURE AFTER STEREOTACTIC RADIOSURGERY FOR RECURRENT HIGH-GRADE GLIOMA: A SINGLE INSTITUTION EXPERIENCE OF 10 YEARS. Neuro-Oncology, 2018, 20, vi230-vi230.	1.2	0
104	CSIG-17. CHARACTERIZATION OF AN ALTERNATIVELY SPLICED NTRK2 VARIANT IN GLIOMA: EMPLOYING NOVEL REAGENTS TO UNCOVER NOVEL FUNCTIONS. Neuro-Oncology, 2018, 20, vi46-vi46.	1.2	0
105	TMIC-13. EFFICACY OF RETINOIC ACID IN REVERSING IMMUNE EVASION IN IDH MUTANT GLIOMAS. Neuro-Oncology, 2018, 20, vi258-vi258.	1.2	0
106	Reply to â€˜Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyâ€™. Nature Reviews Clinical Oncology, 2019, 16, 522-523.	27.6	0
107	PATH-07. MITOTIC INDEX THRESHOLDS DO NOT PREDICT CLINICAL OUTCOME FOR IDH-MUTANT ASTROCYTOMA. Neuro-Oncology, 2019, 21, vi144-vi144.	1.2	0
108	TMOD-30. CHARACTERIZATION OF AN ALTERNATIVELY SPLICED NTRK2 VARIANT IN GLIOMAS. Neuro-Oncology, 2019, 21, vi269-vi269.	1.2	0

#	Article	IF	Citations
109	DDIS-29. BRAIN-PENETRANT MICROTUBULE-TARGETING AGENT, ST-401, KILLS GLIOBLASTOMA THROUGH A NOVEL MECHANISM. Neuro-Oncology, 2019, 21, vi69-vi69.	1.2	0